Remedy is now building the next growth leap of its strategy with the 5 major game projects under development. This will be reflected in rising costs between 2022 and 2023, but enable significant earnings growth particularly in 2025-2026, driven by increasing royalty income. In terms of long-term growth potential, we see the share's risk/return ratio as attractive, but with our lowered forecasts, this will take longer to materialize than previously expected. Thus, in the short term, the attractiveness of the stock has weakened compared to our previous estimates.
Trade. (Remedy)
Remedy Entertainment Plc is a globally successful game company founded in 1995 and based in Espoo, Finland. We create story-driven console and computer games with renowned partners such as 505 Games, Microsoft, Rockstar Games and Smilegate. Remedy has two games under development, CrossFire 2 and Project 7, built using our proprietary Northlight game engine and tools. Our past games include Death Rally, Max Payne, Max Payne 2: The Fall of Max Payne, Alan Wake, Alan Wake’s American Nightmare and Quantum Break.